CON trades 6.0% below Wall Street's consensus target of $38.60.
Last 12 months price action with 12-month analyst target path
The base valuation assumes CON achieves its forward estimates and maintains a stable P/E multiple of 22.1x. This scenario reflects the blended consensus of 6 Wall Street analysts, balancing both positive catalysts and macroeconomic headwinds over the next 12 months.
As of October 7, 2026, Concentra Group Holdings Parent, Inc. (CON) has a Wall Street consensus price target of $38.60, based on estimates from 6 covering analysts. With the stock currently trading at $36.40, this represents a potential upside of +6.0%. The company has a market capitalization of $4.66B.
Analyst price targets range from a low of $30.00 to a high of $42.00, representing a 31% spread in expectations. The median target of $40.00 aligns closely with the consensus average.
The current analyst consensus rating is Buy, with 6 analysts rating the stock as a Buy or Strong Buy,0 rating it Hold, and 0 rating it Sell or Strong Sell. This overwhelmingly bullish sentiment suggests analysts see significant catalysts for upside ahead.
From a valuation perspective, CON trades at a trailing P/E of 28.0x and forward P/E of 22.1x. Analysts expect EPS to grow +6.4% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $38.90, with bear and bull scenarios of $24.51 and $51.26 respectively. Model confidence stands at 50/100, reflecting moderate uncertainty in projections.
| Company | Market Cap | Price | Target | Upside Potential | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 AMSFAMERISAFE, Inc. | $441M | $23.60 | $32.00 | +35.6% | Buy | 11.9x | 6 |
 OHIOmega Healthcare Investors, Inc. | $13.3B | $44.77 | $49.88 | +11.4% | Hold | 16.9x | 28 |
 ACHCAcadia Healthcare Company, Inc. | $2.7B | $29.04 | $34.78 | +19.8% | Buy | 19.0x | 25 |
 SEMSelect Medical Holdings Corporation | $2.0B | $16.51 | $16.50 | -0.1% | Hold | 13.5x | 14 |
 USPHU.S. Physical Therapy, Inc. | $1.3B | $83.63 | $90.00 | +7.6% | Buy | 30.4x | 13 |
 ATIATI Inc. | $26.6B | $194.69 | $248.00 | +27.4% | Buy | 38.5x | 31 |
 ALHCAlignment Healthcare, Inc. | $1.7B | $8.37 | $19.00 | +127.0% | Buy | 46.1x | 16 |
 CCRNCross Country Healthcare, Inc. | $428M | $13.25 | $12.09 | -8.8% | Hold | 143.2x | 14 |
 AMNAMN Healthcare Services, Inc. | $1.4B | $36.73 | $37.00 | +0.7% | Buy | 11.2x | 17 |
 OPCHOption Care Health, Inc. | $4.9B | $31.00 | $28.43 | -8.3% | Buy | 16.5x | 15 |
Quick answers to the most common questions about buying CON stock.
The consensus price target for CON is $38.6, close to the current price of $36.4 (6.0% implied move). Based on 6 analyst estimates, the stock appears fairly valued near current levels.
CON has a consensus rating of "Buy" based on 6 Wall Street analysts. The rating breakdown is predominantly bullish, with 6 Buy/Strong Buy ratings. The consensus 12-month price target of $38.6 implies 6.0% upside from current levels.
CON trades at a forward P/E of 22.0606x, representing a moderate valuation. With analysts targeting $38.6 (6.0% implied move), the stock appears reasonably valued with upside.
The most bullish Wall Street analyst has a price target of $42 for CON, while the most conservative target is $30. The consensus of $38.6 represents the median expectation. Our quantitative valuation model projects a bull case target of $51 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
CON is moderately covered, with 6 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 0 recommend Hold, and 0 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
The 12-month CON stock forecast based on 6 Wall Street analysts shows a consensus price target of $38.6, with estimates ranging from $30 (bear case) to $42 (bull case). The median consensus rating is "Buy". Our proprietary valuation model produces a base case fair value of $39, with bear/bull scenarios of $25/$51.
Our quantitative valuation model calculates CON's fair value at $39 (base case), with a bear case of $25 and bull case of $51. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 50/100.
CON trades at a forward P/E ratio of 22.1x based on next-twelve-months earnings estimates compared to a trailing P/E of 28.0x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
CON appears fairly valued according to analysts, with a "Buy" rating and minimal upside to the $38.6 target. Consider your investment thesis and risk tolerance. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
CON analyst price targets range from $30 to $42, a 31% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $38.6 consensus represents the middle ground. Our model's $25-$51 range provides an independent fundamental perspective.
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.